Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice.

Ksienski, Doran; Truong, Pauline T; Croteau, Nicole S; Chan, Angela; Sonke, Eric; Patterson, Tiffany; Clarkson, Melissa; Lesperance, Mary

Ksienski, Doran; Truong, Pauline T; Croteau, Nicole S; Chan, Angela; Sonke, Eric; Patterson, Tiffany; Clarkson, Melissa; Lesperance, Mary.

Afiliación

Ksienski D; Medical Oncology, British Columbia Cancer Agency, Victoria, CAN.
Truong PT; Radiation Oncology, British Columbia Cancer Agency, Victoria, CAN.
Croteau NS; Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Victoria, CAN.
Chan A; Medical Oncology, British Columbia Cancer Agency, Surrey, CAN.
Sonke E; Internal Medicine, University of British Columbia, Victoria, CAN.
Patterson T; Clinical Trials Unit, British Columbia Cancer Agency, Victoria, CAN.
Clarkson M; Clinical Trials Unit, British Columbia Cancer Agency, Victoria, CAN.
Lesperance M; Mathematics and Statistics, University of Victoria, Victoria, CAN.

Cureus ; 13(11): e19835, 2021 Nov.

Article en En | MEDLINE | ID: mdl-34963849

Palabras clave

immunotherapy; melanoma; nivolumab; pembrolizumab; time to treatment

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Etiology_studies / Prognostic_studies Idioma: En Revista: Cureus Año: 2021 Tipo del documento: Article